JP2012136518A5 - - Google Patents

Download PDF

Info

Publication number
JP2012136518A5
JP2012136518A5 JP2011280781A JP2011280781A JP2012136518A5 JP 2012136518 A5 JP2012136518 A5 JP 2012136518A5 JP 2011280781 A JP2011280781 A JP 2011280781A JP 2011280781 A JP2011280781 A JP 2011280781A JP 2012136518 A5 JP2012136518 A5 JP 2012136518A5
Authority
JP
Japan
Prior art keywords
immunogenic composition
lyophilized
composition according
lyophilized immunogenic
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011280781A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012136518A (ja
JP6097478B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2012136518A publication Critical patent/JP2012136518A/ja
Publication of JP2012136518A5 publication Critical patent/JP2012136518A5/ja
Application granted granted Critical
Publication of JP6097478B2 publication Critical patent/JP6097478B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011280781A 2010-12-22 2011-12-22 黄色ブドウ球菌(Staphylococcusaureus)抗原の安定な免疫原性組成物 Expired - Fee Related JP6097478B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201061426476P 2010-12-22 2010-12-22
US61/426,476 2010-12-22

Publications (3)

Publication Number Publication Date
JP2012136518A JP2012136518A (ja) 2012-07-19
JP2012136518A5 true JP2012136518A5 (cg-RX-API-DMAC7.html) 2015-01-29
JP6097478B2 JP6097478B2 (ja) 2017-03-15

Family

ID=45444677

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011280781A Expired - Fee Related JP6097478B2 (ja) 2010-12-22 2011-12-22 黄色ブドウ球菌(Staphylococcusaureus)抗原の安定な免疫原性組成物

Country Status (18)

Country Link
US (1) US20130259896A1 (cg-RX-API-DMAC7.html)
EP (2) EP2654784B1 (cg-RX-API-DMAC7.html)
JP (1) JP6097478B2 (cg-RX-API-DMAC7.html)
KR (2) KR101808398B1 (cg-RX-API-DMAC7.html)
CN (1) CN103826656B (cg-RX-API-DMAC7.html)
AU (1) AU2011346535B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013016153A2 (cg-RX-API-DMAC7.html)
CA (1) CA2819120C (cg-RX-API-DMAC7.html)
DK (2) DK3150222T3 (cg-RX-API-DMAC7.html)
ES (2) ES2769425T3 (cg-RX-API-DMAC7.html)
HU (2) HUE033072T2 (cg-RX-API-DMAC7.html)
IL (1) IL226793B (cg-RX-API-DMAC7.html)
MX (1) MX350170B (cg-RX-API-DMAC7.html)
PL (2) PL2654784T3 (cg-RX-API-DMAC7.html)
PT (2) PT3150222T (cg-RX-API-DMAC7.html)
RU (1) RU2570730C2 (cg-RX-API-DMAC7.html)
SI (2) SI2654784T1 (cg-RX-API-DMAC7.html)
WO (1) WO2012085872A2 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2893938B1 (en) 2004-09-22 2019-03-06 GlaxoSmithKline Biologicals SA Immunogenic composition for use in vaccination against Staphylococcei
PE20110023A1 (es) 2009-06-22 2011-01-31 Wyeth Llc Composiciones inmunogenicas de antigenos de staphylococcus aureus
EP3461496B1 (en) 2009-06-22 2023-08-23 Wyeth LLC Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
MX2012013664A (es) * 2010-06-04 2013-01-24 Wyeth Llc Formulaciones de vacuna.
AU2012266880A1 (en) * 2011-03-16 2013-10-03 Regents Of The University Of Minnesota Compositions and methods for inducing immune responses against bacteria in the genus staphylococcus
GB201310008D0 (en) * 2013-06-05 2013-07-17 Glaxosmithkline Biolog Sa Immunogenic composition for use in therapy
JP2016540764A (ja) * 2013-12-04 2016-12-28 グリコヴァキシン アーゲー 大腸菌で合成された糖タンパク質ワクチンによる黄色ブドウ球菌感染の予防
IL310015B1 (en) * 2013-12-31 2025-10-01 Access To Advanced Health Inst Single vial formulation
US20170100476A1 (en) * 2014-04-10 2017-04-13 Asit Biotech S.A. Hsp-free allergen preparation
KR20200040812A (ko) * 2017-08-16 2020-04-20 머크 샤프 앤드 돔 코포레이션 폐렴구균 접합체 백신 제제
GB201802339D0 (en) 2018-02-13 2018-03-28 Glaxosmithkline Biologicals Sa Immunogenic composition
KR102649069B1 (ko) 2018-05-31 2024-03-19 주식회사 엑소코바이오 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 안면 홍조 개선용 조성물
CN112261871B (zh) 2018-07-28 2022-05-17 韩国外泌体生技有限公司 用于使外排体冻干的方法
KR102163806B1 (ko) 2018-07-30 2020-10-07 주식회사 엑소코바이오 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 피지분비 감소용 조성물
US20230151102A1 (en) * 2020-01-13 2023-05-18 Aptevo Research And Development Llc Methods and compositions for preventing adsorption of therapeutic proteins to drug delivery system components

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902506A (en) 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
EP0138854B1 (en) 1983-03-08 1992-11-04 Chiron Mimotopes Pty. Ltd. Antigenically active amino acid sequences
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
US5078996A (en) 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
US5571515A (en) 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6008341A (en) 1994-08-22 1999-12-28 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin S. aureus fibrinogen binding protein gene
BE1008978A5 (fr) 1994-12-27 1996-10-01 Solvay Adjuvants pour vaccins.
WO1997014800A1 (en) 1995-10-16 1997-04-24 Smithkline Beecham Plc Novel saliva binding protein
GB9622159D0 (en) 1996-10-24 1996-12-18 Solvay Sociutu Anonyme Polyanionic polymers as adjuvants for mucosal immunization
GB9622660D0 (en) 1996-10-31 1997-01-08 Biocine Spa Immunogenic detoxified mutant toxin
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
AU1537699A (en) 1997-11-26 1999-06-15 Bioresearch Ireland a division of Eolas - The Irish Science and Technology Agency Extracellular matrix-binding proteins from (staphylococcus aureus)
US6680195B1 (en) 1997-11-26 2004-01-20 Inhibitex, Inc. Extracellular matrix-binding proteins from staphylococcus aureus
MXPA01002119A (es) * 1998-08-31 2003-03-27 Inhibitex Inc Vacunas multicomponentes.
US6936258B1 (en) 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
US7115730B1 (en) 1999-04-27 2006-10-03 Chiron Srl Immunogenic detoxified mutant E. coli LT-A-toxin
US7384640B1 (en) 1999-09-30 2008-06-10 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant
BRPI0111639B8 (pt) 2000-06-08 2021-05-25 Intercell Ag uso de uma molécula de ácido oligodeoxinucléico imunoestimulatório e composição farmacêutica.
AT410635B (de) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
JP2004535187A (ja) 2001-06-07 2004-11-25 ワイス・ホールデイングス・コーポレーシヨン アジュバントとしてのコレラホロトキシンの突然変異形
WO2002098369A2 (en) 2001-06-07 2002-12-12 Wyeth Holdings Corporation Mutant forms of cholera holotoxin as an adjuvant
EP2339344A1 (en) 2001-06-15 2011-06-29 Inhibitex, Inc. Cross-reactive monoclonal and polyclonal antibodies which recognize surface proteins from coagulase-negative staphylococci and staphylococcus aureus
GB0118249D0 (en) * 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
NZ561879A (en) 2003-03-07 2009-05-31 Wyeth Corp Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections
US20060251675A1 (en) 2003-03-17 2006-11-09 Michael Hagen Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
EP2893938B1 (en) * 2004-09-22 2019-03-06 GlaxoSmithKline Biologicals SA Immunogenic composition for use in vaccination against Staphylococcei
EP2476433A1 (en) * 2006-03-30 2012-07-18 GlaxoSmithKline Biologicals S.A. Immunogenic composition
AR060188A1 (es) * 2006-03-30 2008-05-28 Glaxosmithkline Biolog Sa Procedimiento de conjugacion
GB0606416D0 (en) * 2006-03-30 2006-05-10 Glaxosmithkline Biolog Sa Immunogenic composition
WO2007127668A2 (en) 2006-04-26 2007-11-08 Wyeth Novel processes for coating container means which inhibit precipitation of polysaccharide-protein conjugate formulations
EP2086581B1 (en) * 2006-11-07 2014-08-13 Sanofi Pasteur Biologics, LLC Stabilization of vaccines by lyophilization
ES2615390T3 (es) 2008-03-05 2017-06-06 Sanofi Pasteur Proceso para estabilizar una composición de vacuna que contiene adyuvante
PE20110023A1 (es) * 2009-06-22 2011-01-31 Wyeth Llc Composiciones inmunogenicas de antigenos de staphylococcus aureus

Similar Documents

Publication Publication Date Title
JP2012136518A5 (cg-RX-API-DMAC7.html)
RU2013128277A (ru) СТАБИЛЬНЫЕ ИММУНОГЕННЫЕ КОМПОЗИЦИИ АНТИГЕНОВ Staphylococcus aureus
HRP20211417T1 (hr) Formulacije koje stabiliziraju i sprječavaju taloženje imunogenih pripravaka
JP2016520075A5 (cg-RX-API-DMAC7.html)
UA116364C2 (uk) Рідка композиція протеїнового кон'югата, що містить оксинтомодулін та фрагмент імуноглобуліну
PH12017500844A1 (en) Stable protein solution formulation containing high concentration of an anti-vegf antibody
RU2017104529A (ru) Композиции neisseria meningitidis и способы их применения
WO2007130493A3 (en) Cd40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity
HRP20160276T1 (hr) Pripravci za imuniziranje protiv bakterije staphylococcus aureus
HRP20201268T1 (hr) Stabilne formulacije koje sadrže anti-pcsk9 antitijela
JP2015231997A5 (cg-RX-API-DMAC7.html)
HRP20210242T1 (hr) Stabilne formulacije antigena iz bakterije neisseria meningitidis rlp2086
JP2012501332A5 (cg-RX-API-DMAC7.html)
JP2014040441A5 (cg-RX-API-DMAC7.html)
JP2014139229A5 (cg-RX-API-DMAC7.html)
JP2012521201A5 (cg-RX-API-DMAC7.html)
JP2011528222A5 (cg-RX-API-DMAC7.html)
EA201490804A1 (ru) Препараты этанерцепта, стабилизированные хлоридом натрия
NO20090177L (no) Vaksiner for malaria
EA200870264A1 (ru) Композиция антител
FI3725330T3 (fi) Polypeptidien stabiilit valmisteet ja niiden käyttötarkoitukset
JP2016502551A5 (cg-RX-API-DMAC7.html)
JP2014525429A5 (cg-RX-API-DMAC7.html)
JP2013531679A5 (cg-RX-API-DMAC7.html)
JP2017514868A5 (cg-RX-API-DMAC7.html)